Letter: Clinical and experimental effects of dipyridamole.
D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D002176:Candida albicans / Q000302:isolation & purification; D004176:Dipyridamole / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D004731:Endotoxins / Q000009:adverse effects; D004903:Erythrocyte Aggregation / Q000139:chemically induced / Q000188:drug therapy*; D005337:Fibrin / Q000502:physiology; D005340:Fibrinogen / Q000502:physiology; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D018805:Sepsis / Q000150:complications
D000893:Anti-Inflammatory Agents; D004731:Endotoxins; D005343:Fibrinolytic Agents; D004176:Dipyridamole; D005337:Fibrin; D005340:Fibrinogen; D006493:Heparin